Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Top 20 pharma companies by 2023 revenue - Fierce Pharma
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...
Roche projected to claim pharma's 2025 sales crown: Evaluate
Jan 3, 2025 · Evaluate first pegged Roche to become the top drugmaker by prescription sales in its 2024 preview, estimating the Swiss firm would generate pharma revenue for the year approaching $54 billion.. At ...
Novartis readies intrathecal Zolgensma for older SMA patients
Jan 2, 2025 · Zolgensma as an intravenous infusion has been approved in the U.S. for children under 2 years with SMA since 2019. The intrathecal version injects the gene therapy directly into the spinal cord ...
FDA approves BMS' subcutaneous Opdivo with some limitations
Jan 2, 2025 · For healthcare facilities, Opdivo Qvantig could reduce burdens related to infusion capacity; for patients, it cuts the treatment time for receiving a checkpoint inhibitor from a 30-minute infusion ...
The top 15 blockbuster patent expirations coming this decade
Jul 12, 2021 · Looking out over the next decade, some of the biggest drugs in the industry will tumble off the patent cliff, putting pharma giants in the hot seat as investors clamor for their next blockbuster.
Lilly's Mounjaro will be in short supply through April, FDA says
Apr 2, 2024 · The company acknowledged that some patients may struggle to fill their prescriptions due to “the unprecedented demand for these medicines,” a Lilly spokesperson recently told Fierce Pharma ...
The top 20 drugs by worldwide sales in 2023 | Fierce Pharma
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as ...
After two rejections, FDA approves Mesoblast's GVHD cell therapy
Dec 19, 2024 · An FDA advisory panel vote of 9-1 to recommend the approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company.. More than four ...
Compounders protest as FDA removes tirzepatide off shortage list
Dec 19, 2024 · The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...